Teva Pharmaceutical has acquired Merck's Theramex, a company into women's health business.
Previously, Teva Pharma has signed an agreement with Theramex to take over the distribution rights of Theramex’s products sold in Spain and Brazil and several other countries.
Under the terms of the agreement, Theramex was entitled to get EUR265m in closing of the transaction.
Theramex products include an oral contraceptive, NOMAC/E2, which showed positive results in a Phase 3 trial, now has been submitted for regulatory approval in Europe.
Theramex is also developing, in partnership with Merck & Co, nomegestrol acetate (2.5mg)/17beta-estradiol (1.5mg), a combined oral contraceptive containing a combination of a natural estrogen identical to the estrogen produced by the woman’s own body and a selective progestin, currently in registration in Europe